Biocytogen
Biocytogen is a global biotech company advancing antibody discovery and drug development through innovative technologies. Through its RenSuper™ Biologics sub-brand, Biocytogen drives the discovery of fully human monoclonal, bispecific, multispecific, ADC, VHH, and TCR-mimic antibodies across 1,000+ druggable targets, providing 1M+ fully human antibody sequences for 400+ global partnerships. RenSuper™ Workstation, its AI-powered antibody discovery platform, compresses early discovery timelines from years to months.
Leveraging its gene-editing expertise, Biocytogen pioneered drug target knock-in humanized models and offers 5,500+ models via BioMice™, along with one-stop pharmacology and custom gene-editing services. BioMice™ has completed 8,600+ global drug evaluation projects.
